T1	Participants 432 571	1,146 patients with AF and risk of stroke were randomised to edoxaban 30 mg qd, 30 mg bid, 60 mg qd, or 60 mg bid or warfarin dose-adjusted
T2	Participants 974 982	patients
T3	Participants 1473 1479	groups
T4	Participants 1504 1548	edoxaban 30 and 60 mg qd in patients with AF
